Physician profile
Thomas M Pinson
NPI 1326021262
$8,842.38
in general payments reported to CMS, 2019-2025
52 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $785 · 2021: $1,845 · 2022: $1,634 · 2023: $1,605 · 2024: $894 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,418.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,517.65 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $684.79 | 2019-2025 | Rexulti, Abilify Maintena |
| Ironwood Pharmaceuticals, INC | $619.06 | 2020-2025 | Linzess |
| Glaxosmithkline, LLC. | $560.16 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $485.07 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $388.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $317.24 | 2019-2025 | Trintellix |
| Allergan, INC. | $289.70 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.31 | 2021-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $222.29 | 2020-2025 | Gvoke Hypopen |
| Uswm, LLC | $197.70 | 2022-2023 | Lucemyra, Zimhi |
| Alkermes, INC. | $194.43 | 2019-2023 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.63 | 2019-2023 | Ofev |
| Medline Industries LP | $148.17 | 2019 | |
| Gilead Sciences, INC. | $145.38 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.